Clinical trials: Glut1 Deficiency Syndrome
- Condition Glut1 Deficiency Syndrome
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
The primary objectives of the study are to evaluate the efficacy of UX007 compared to placebo as measured by the reduction from randomization to Week 8 in frequency of seizures and to evaluate the safety of UX007 via adverse…
- Trial name
- NCT01993186
- Testing
- UX007
- Where
- 14 sites in United States, Australia and 5 more
- Volunteers
- 36 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
The primary objective of the study was to evaluate the efficacy and safety of UX007 in the treatment of disabling paroxysmal movement disorders associated with Glut1 DS.
- Trial name
- NCT02960217
- Testing
- UX007
- Where
- 12 sites in United States, France and 4 more
- Volunteers
- 44 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Glucose Transporter Type 1 Deficiency Syndrome
Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)
The primary objective of the study is to evaluate the long-term safety of UX007 in Glut1 DS participants.
- Trial name
- NCT02599961
- Testing
- UX007
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 15 people
- Sponsor
- Ultragenyx Pharmaceutical Inc